CMA scrutinises de-branding of generics

On 7 December 2016, the Competition and Markets Authority announced its finding that pharmaceutical manufacturer Pfizer Limited and its distributor Flynn Pharma Limited had abused their respective dominant positions by imposing unfair prices for an anti-epilepsy drug (phenytoin sodium capsules), following a price rise of the drug from £2.83 to £67.50 per pack.

Page 1 of 212